Riskpilot← Back to searchSign inGet full accessDextra Lapsettomuusklinikka Oy
OYActiveY-tunnus 2563086-9Kehräsaari -BMedical specialists activities · NACE 8622Est. 2013— employees
Revenue 2024
EUR 5,4M
+7% vs 2023
EBITDA margin
17.1%
+57% vs 2023
Equity ratio
68.5%
Financial strength
Net profit 2024
EUR 705K
+118% vs 2023
| Revenue | EUR 5,4M | +7% |
| EBITDA | EUR 929K | +57% |
| Net profit | EUR 705K | +118% |
| Total assets | EUR 2,8M | +49% |
| Equity | EUR 1,9M | +59% |
| Employees | — | — |
Legal name
Dextra Lapsettomuusklinikka Oy
Y-tunnus number
2563086-9
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
9. elokuuta 2013
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on lapsettomuushoitojen, gynekologisten vastaanottopalveluiden, ultraäänitutkimusten, äitiysneuvolapalveluiden, perinatologin vastaanottopalveluiden, lääketieteellisen genetiikan palveluiden, lääketieteellisten laboratoriopalveluiden ja lääkäreiden sekä muiden terveydenhuollon ammattihenkilöiden vastaanottopalveluiden tuottaminen. Yhtiö voi toimintaansa varten omistaa ja hallita tiloja sekä luovuttaa niitä käytettäväksi edellä mainittujen palveluiden tuottamiseen.
Address
Kehräsaari -B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 5 425 | 5 980 | 5 201 | 5 100 | 5 445 |
| Staff expenses | −1 121 | −1 425 | −1 625 | −1 629 | −1 751 |
| EBITDA | 1 346 | 1 373 | 812 | 592 | 929 |
| Depreciation & amort. | −230 | −247 | −273 | −289 | −119 |
| EBIT | 1 116 | 1 126 | 538 | 303 | 810 |
| Net financials | −26 | −25 | 82 | 28 | 48 |
| Profit before tax | 1 090 | 1 035 | 549 | 392 | 879 |
| Tax | 213 | 203 | 106 | 69 | 174 |
| Net profit | 877 | 832 | 443 | 324 | 705 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 858 | 2 370 | 1 575 | 1 848 | 2 759 |
| Equity | 1 369 | 1 816 | 971 | 1 185 | 1 890 |
| Long-term debt | 12 | 13 | 27 | 0 | 0 |
| Short-term debt | 476 | 540 | 577 | 587 | 813 |
| Total debt | 488 | 554 | 604 | 587 | 813 |
EBITDA margin
17.1%
This company
15.8%
Market median
+8% vs market
20202024
Equity ratio
68.5%
This company
38.2%
Market median
+79% vs market
20202024
Return on equity
37.3%
This company
18.4%
Market median
+103% vs market
20202024
Net profit margin
12.9%
This company
8.1%
Market median
+59% vs market
20202024
Asset turnover
1.97×
This company
1.12×
Market median
+76% vs market
20202024
Debt / equity
0.46×
This company
0.62×
Market median
+26% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AM Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (5) | ||
MM Chief Executive Officer | Chief Executive Officer | 2018 – 2019 |
RH Chief Executive Officer | Chief Executive Officer | 2019 – 2021 |
LI Audit | Audit | 2016 – 2022 |
AT | Audit | 2022 – 2023 |
ES Chief Executive Officer | Chief Executive Officer | 2021 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2026 | |
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Chairperson | 2026 | |
| Former (8) | ||
| Chairperson | 2022 – 2024 | |
| Board of Directors | 2018 – 2023 | |
| Chairperson | 2024 – 2025 | |
| Chairperson | 2019 – 2022 | |
| Board of Directors | 2023 – 2024 | |
| Chairperson | 2025 – 2026 | |
| Board of Directors | 2018 – 2023 | |
| Chairperson | 2018 – 2019 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dextra Lapsettomuusklinikka Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Minna Marika Elomaa | Chief Executive Officer | 0 companies |
| Riia Heidi Johanna Siivikko | Chief Executive Officer | 0 companies |
| Lotta Irina Nurminen | Audit | 0 companies |
| Anna Marika Mikola | Chief Executive Officer | 0 companies |
| Assi Talvikki Lintula | Audit | 0 companies |
| Esa Sakari Mäkelä | Chief Executive Officer | 0 companies |
| Joni Raimo Mikael Aaltonen | Chairperson | 0 companies |
| Saila Hanne Marika Haatainen | Board of Directors | 0 companies |
| Eero Jaakko Varila | Board of Directors | 0 companies |
| Lasse Arvi Parvinen | Board of Directors | 0 companies |
| Tuomas Risto-Matias Hyyryläinen | Chairperson | 0 companies |
| Sanna Maarit Uotila | Board of Directors | 0 companies |
| Teija Johanna Kulmala | Chairperson | 0 companies |
| Marko Tapio Savolainen | Board of Directors | 0 companies |
| Anu Hannele Kallio | Chairperson | 0 companies |
| Niklas Henrik Simberg | Board of Directors | 0 companies |
| Ville Sakari Lehtonen | Chairperson | 0 companies |
| Mika Kalevi Uotila | Chairperson | 0 companies |